The Global Chinese Financial Forum – Shanghai Conference 2017 will bring together an audience of pre-qualified Chinese pharmaceutical companies and financial groups ready to invest, joint venture, or enter into licensing arrangements with overseas life science companies.
China is leading the ‘pharmerging’ (emerging pharmaceutical) markets with a projected average market growth of 15% to 18% (2012-2017), and it is growing faster than almost all developed markets including the US and Canada.
As China’s role in the global economy grows, so too has China’s stature in global finance. Nowhere is this more readily seen than in the life sciences sector. Fueled by rapidly growing product sales, an aging population and a rising middle class, investments into global life sciences projects have increased year over year.
This growth has led to significant opportunities for global life science companies that are focused on developing new pharmaceuticals, medical devices and other products in terms of capital raising and commercialization.
Private meetings with high net worth investors, institutional investors, funds, and industrial investors. Networking opportunities through luncheons and other events.
Keynote speeches by experts from world-leading healthcare industries. Corporate Presentation in front of Pre-Qualified individual and institutional strategic investors.
Full Chinese interpretation support for presentations, meetings and marketing materials.
Shanghai has the highest concentration of medical R&D resources inChina and also houses intensive multinational pharmaceutical industryR&D centers from multinational companies such as Pfizer,GlaxoSmithKline, AstraZeneca, Novartis, Roche and Thermo FisherScientific. Shanghai achieved 6.6% of total R&D investment in 2013,which was $13B Canadian dollars.
If any companies would like to sponsor or speak at the GCFF Shanghai Conference 2017, please contact us soon as spots are limited.